Drug Targets – News and Features
News
BIOBASE to Coordinate EU-backed Project to Develop Technology for Studying Mechanisms of Disease
The three-year, 3 million Euro project, called Net2Drug, will be coordinated by BIOBASE and developed as a collaboration with several international participants.
News
Procognia Enters Protein Kinase Array Collaboration with GSK
Procognia will combine its protein array technology with GSK’s fluorescently-labelled kinase inhibitors to enable GSK to profile its kinase hits in-house.
News
Argenta Discovery Announces Second Two-Year Drug Discovery Collaboration with Genentech
Argenta to use its expertise in computer-aided drug design, medicinal chemistry and biology to discover new chemical entities acting against a second drug target defined by Genentech.
News
Graffinity and Amgen Enter into Drug Discovery Research Agreement
Graffinity receives access fees for the generation of small molecule hits against drug targets while Amgen will use Graffinity’s fragment-based drug discovery technology to screen small molecule fragments.
News
Cellzome Announces Extension of Drug Discovery Collaboration with Ortho-McNeil Pharmaceutical
The collaboration provides Ortho-McNeil Pharmaceutical and its affiliate J&JPRD with Cellzome’s Amyloid Precursor Protein processing pathway map.
News
LifeSpan BioSciences Enters into Agreement with Roche for Expanded DrugTarget™ Localization Database
Roche Pharma will gain access to all the features of the CNS subset of the DrugTarget Database™.
News
Study Identifies Common Flaws in Oncology Microarray Studies
A study in the Journal of the National Cancer Institute reports a percentage of critical flaws in analysis of microarray-based studies in oncology.
News
Applied Biosystems Announces New Molecular Tools to Speed Drug Discovery Research
The TaqMan Gene Signature Panels enables researchers to observe the expression level of genes that encode proteins involved with critical cellular functions.
News
Albany Announces Drug Discovery Research Collaboration with Bristol-Myers Squibb
Albany will test samples with the goal of identifying hit compounds from its natural product hit seeking collections against multiple drug targets.
News
Launch of New Center for Proteomics and Drug Actions
Vanderbilt University Medical Center and the National Foundation for Cancer Research have established a cancer research center from $1 million funded by NFCR.
Advertisement